在药物基因组学的指导下治疗耐药高血压:一个随机控制的开放标签试验
Ai Wang1, Muisha Bienvenue Mbikyo1, Junzhe Zhang1
1Department of Cardiology, The First Hospital of China Medical University, Shenyang, China.
概括
与标准护理相比,药物基因组学 (PGx) 指导的治疗显著降低了耐药高血压 (RH) 患者的血压. 这项临床研究突出了PGx的重点.
科学领域:
- 心脏病学和临床药理学
- 遗传学和精准医学 遗传学和精准医学
背景情况:
- 抗性高血压 (RH) 在心血管疾病管理中构成了重大挑战.
- 药物基因组学 (PGx) 提供了一个个性化的方法来优化抗高血压药物选择和剂量.
- 评估PGx引导治疗对于改善RH治疗结果至关重要.
研究的目的:
- 评估药物基因组学 (PGx) 导向治疗与基于共识的治疗对抗性高血压 (RH) 患者的疗效和安全性.
- 确定PGx对降低血压和RH的临床结果的影响.
主要方法:
- 一项随机控制的开放标签研究与59名RH患者进行.
- 干预组接受了12周的PGx引导治疗,考虑了10个基因和31种药物.
- 对照组接受了基于共识的标准治疗;主要结局是12周后静缩血压 (SBP) 的变化.
主要成果:
- 与对照组 (p<0.003) 相比,PGx引导的治疗导致静脉血压 (SBP) (31.26 mmHg vs 14.61 mmHg) 和透气血压 (DBP) (19.61 mmHg vs 7.81 mmHg) 的降低显著更大 (p<0.003).
- 副作用是相似的,干预组有一次心脏病发作,对照组有一次心力衰竭.
- 干预组的1名患者和对照组的6名患者发现肝功能不全;两组的5名患者出现功能不全.
结论:
- 药物基因组学引导的治疗显著改善了耐药高血压患者的血压控制.
- PGx指导治疗是管理RH的安全有效策略,为标准护理提供优越的结果.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
01:25Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
153
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
153